This inventor holds 3 USPTO granted patents. Top assignees: Bioprobes, Inc., G.d. Searle & Company, Pharmacia Corporation. Active years: 1999-2003.
Company Filing History:
1 out of 2 
1 out of 1,323 
1 out of 220 
Years Active: 1999-2003
Title: The Innovations of Barbara L Schwartz
Introduction
Barbara L Schwartz is a notable inventor based in Washington, DC. She has made significant contributions to the field of Alzheimer's research, holding three patents that focus on improving cognitive functions in patients afflicted with this disease. Her work is characterized by a commitment to enhancing the quality of life for those affected by Alzheimer's.
Latest Patents
One of her latest patents is titled "Use of amino-isoxazolidone compounds for improvement of lexical priming." This patent describes a class of amino-isoxazolidone compounds that are utilized to enhance lexical priming in patients susceptible to or afflicted with Alzheimer's Disease. Among the preferred compounds in this class are D-cycloserine and its prodrugs. Another significant patent is "Use of amino-isoxazolidone compounds for improvement of implicit memory," which details the use of D-4-amino-3-isoxazolidone to improve implicit memory in similar patient populations.
Career Highlights
Throughout her career, Barbara has worked with reputable companies such as Bioprobes, Inc. and Pharmacia Corporation. Her experience in these organizations has allowed her to develop and refine her innovative ideas, contributing to advancements in medical research and treatment options for Alzheimer's Disease.
Collaborations
Barbara has collaborated with esteemed colleagues, including Stephen I Deutsch and Robert L Herting. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and the development of groundbreaking research.
Conclusion
Barbara L Schwartz's contributions to the field of Alzheimer's research through her patents and collaborations highlight her dedication to improving cognitive health. Her innovative work continues to inspire advancements in the treatment of this challenging disease.